Jena, Germany | April 2, 2020 | Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approx. EUR 715 million (previous year EUR 667.2 million) in the first six months of fiscal year 2019/20, based on preliminary data. Growth slowed significantly during the second quarter 2019/20, corresponding to revenue of approx. EUR 345 million (previous year EUR 343.5 million), about the prior year’s level.
Further business results are not yet available at this point. The detailed results of the first six months of fiscal year 2019/20 will be published on May 11, 2020.
In light of the SARS-CoV-2 virus, which is currently spreading globally, and the associated negative effects on the global economy, management expects business development to be significantly impacted in the second half of 2019/20.
A reliable forecast of business development is currently not possible. For this reason, the executive management of Carl Zeiss Meditec will no longer abide by the forecast published in the annual report on Dec 6, 2019 for fiscal year 2019/20. As soon as providing a new forecast for the rest of the financial year becomes feasible, the company will publish it immediately.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and SDax of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med